TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 SAM Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 SAM Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 SAM Non-Alcoholic Steatohepatitis Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South And Central America PEST Analysis
4.3 Experts Opinion
5. SAM Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market– SAM Analysis
6.1 SAM Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
7. SAM Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.3.1 Overview
7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
7.4 Ocaliva
7.4.1 Overview
7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)
7.5 Elafibranor
7.5.1 Overview
7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)
7.6 Selonsertib & Cenicriviroc
7.6.1 Overview
7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)
8. SAM Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.3.1 Overview
8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diagnosis
8.4.1 Overview
8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
9. SAM Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Online Provider
9.5.1 Overview
9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
10. SAM Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis
10.1 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028
10.1.1 Overview
10.1.3 South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
10.1.3.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.1.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.1.2 Brazil: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.1.3.1.3 Brazil: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)
10.1.3.1.4 Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.2 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.2.1 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.2.2 Argentina: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.1.3.2.3 Argentina: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)
10.1.3.2.4 Argentina: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)
10.1.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.3.1 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.3.2 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.1.3.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)
10.1.3.3.4 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel, 2019–2028 (USD Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Cadila Pharmaceuticals Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Intercept Pharmaceuticals, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novartis AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Galmed Pharmaceuticals.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GENFIT.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Siemens Healthineers AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Laboratory Corporation of America Holdings
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms